Kilpest India is locked at upper circuit limit of Rs. 147.20, up by 13.35 points or 9.97% from its previous closing of Rs. 133.85 on the BSE.
The scrip opened at Rs. 147.20 and has touched a high and low of Rs. 147.20 and Rs. 147.20 respectively. So far 12353 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 180.50 on 12-May-2020 and a 52 week low of Rs. 54.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 147.20 and Rs. 117.15 respectively. The current market cap of the company is Rs. 100.50 crore.
The promoters holding in the company stood at 38.19%, while Non-Institutions held 61.81% stake in the company.
Kilpest India has received an order for supply of 5,00,000 tests of TRUPCR VIRAL RNA EXTRACTION Kit, to be used for testing of Covid19 (Corona Virus) from HLL Infratech Services (HITES), Noida, on behalf Indian Council for Medical Research (ICMR). The total value of order is Rs 5.09 crore including GST.
Further, the company has also received order for supply of 14,00,000 tests of TRUPCR SARSCoV2 RT qPCR Kit (RealTime PCR based detection of SARSCoV2 virus) to be used for testing of Covid19 (Corona Virus) from HLL Infratech Services, (HITES), Noida, on behalf Indian Council for Medical Research (ICMR). The total value of order is Rs 60.99 crore including GST.
The company is honored to supply its TRUPCR VIRAL RNA EXTRACTION KIT and TRUPCR SARSCoV2 RT qPCR Kit (RealTime PCR based detection of SARSCoV2 virus) to ICMR, Government of India. This would help company in increasing its Brand image and reach across globe, as a trusted supplier of its products.
Kilpest India is one of India's leading agri-based companies. The Company manufactures, imports, exports, buys, and sells biological compounds derived from plants, animals, micro organisms.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 534.85 |
| Poly Medicure | 1468.25 |
| Laxmi Denta | 195.10 |
| Nureca Ltd. | 263.80 |
| Hemant Surgical Inds | 297.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: